{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=24", "query": { "condition": "Sars-CoV2", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 1235, "total_pages": 124, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T14:35:13.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04707664", "title": "Sargramostim Use in COVID-19 to Recover Patient Health", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19", "SARS-CoV Infection" ], "interventions": [ { "name": "Sargramostim", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Partner Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2021-04-27", "completion_date": "2022-01-31", "has_results": true, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04707664" }, { "nct_id": "NCT04927065", "title": "A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273.211", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.617.2", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.213", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.529", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.214", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.222", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.815", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.231", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5161, "start_date": "2021-05-28", "completion_date": "2023-11-17", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 23, "location_summary": "Sacramento, California • Hollywood, Florida • Jacksonville, Florida + 18 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927065" }, { "nct_id": "NCT06404099", "title": "RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long COVID-19", "Hypersomnia" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Modafinil Placebo", "type": "DRUG" }, { "name": "Solriamfetol", "type": "DRUG" }, { "name": "Solriamfetol Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2024-08-12", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06404099" }, { "nct_id": "NCT04540185", "title": "A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19", "SARS (Severe Acute Respiratory Syndrome)", "SARS-CoV Infection", "SARS-CoV-2" ], "interventions": [ { "name": "Biological: oral polio vaccine", "type": "BIOLOGICAL" }, { "name": "Comparable Placebo", "type": "BIOLOGICAL" }, { "name": "NA-831", "type": "DRUG" }, { "name": "Comparable Placebo of drug", "type": "DRUG" }, { "name": "Combination of oral polio vaccine and NA-831", "type": "COMBINATION_PRODUCT" }, { "name": "Comparable Placebo of Oral Polio Vaccine and Placebo of drug", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3600, "start_date": "2020-11-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04540185" }, { "nct_id": "NCT05877508", "title": "Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Post-Acute Sequela of COVID-19", "Post-Acute COVID-19" ], "interventions": [ { "name": "AER002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Michael Peluso, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-08-01", "completion_date": "2026-07-31", "has_results": true, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877508" }, { "nct_id": "NCT04435808", "title": "Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-04-14", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435808" }, { "nct_id": "NCT04579549", "title": "Repeat Testing for SARS-CoV-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "COVID-19", "Sars-CoV-2" ], "interventions": [ { "name": "Saliva Assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 464, "start_date": "2020-09-29", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04579549" }, { "nct_id": "NCT04346615", "title": "Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19 Infection" ], "interventions": [ { "name": "Zavegepant (BHV-3500)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2020-04-25", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Charleston, South Carolina", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04346615" }, { "nct_id": "NCT05367843", "title": "A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SARS-CoV-2 Infection" ], "interventions": [ { "name": "PRIME-2-CoV_Beta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Speransa Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 103, "start_date": "2022-06-20", "completion_date": "2023-11-08", "has_results": false, "last_update_posted_date": "2024-02-09", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 5, "location_summary": "Florida City, Florida • Chicago, Illinois • Kansas City, Missouri + 2 more", "locations": [ { "city": "Florida City", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Fayetteville", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05367843" }, { "nct_id": "NCT04447404", "title": "DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "DUR-928", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Durect", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2020-09-21", "completion_date": "2021-03-04", "has_results": true, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-10-23T14:35:13.812Z", "location_count": 1, "location_summary": "Newark, New Jersey", "locations": [ { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447404" } ] }